Glioblastoma is notorious for its resilience against conventional treatments like surgery, radiotherapy, and chemotherapy, with median survival rates seldom exceeding a year post-diagnosis. A formidable challenge in treatment stems from the tumor’s ability to exploit the body’s own biological systems to shield itself from therapeutic assault. The University of Reading’s innovative research targets this cunning defense mechanism by employing secretomes—protein-rich secretions from neural crest-derived stem cells—that effectively disrupt the cancer’s protective signaling pathways. This strategy goes beyond merely attacking the tumor cells; it reprograms the tumor microenvironment and immune response, tipping the balance against tumor survival.

In vitro assays utilizing human glioblastoma cells introduced into murine brain tissue revealed that the stem cell secretomes act on multiple fronts: they reduce tumor proliferation rates, lower the invasive capacity of cancer cells that typically enables metastatic spread within the brain, and shrink tumor masses. When combined with temozolomide—the frontline chemotherapeutic agent in glioblastoma therapy—the secretomes amplified the drug’s antitumor activity without inflicting damage on surrounding healthy brain cells. This synergy suggests an enhanced therapeutic window that could improve clinical outcomes and minimize adverse effects.

At the molecular level, the secreted proteins appear to target and neutralize specific signaling cascades that glioblastoma cells employ to manipulate host immune defenses and foster a pro-tumorigenic inflammatory milieu. Professor Darius Widera, the study’s lead investigator, explains that glioblastoma cells send immunomodulatory signals which enlist systemic immune tolerance, effectively “disarming” the patient’s natural anti-tumor immunity. The stem cell proteins disrupt these signals and simultaneously activate complementary pathways that promote inflammation hostile to the tumor, thus “flipping” the cancer’s own defensive mechanisms against itself. This dual-pathway inflammatory rebalancing represents a novel therapeutic paradigm in neuro-oncology.

Further emphasizing the clinical significance, co-author Dr. Graeme Cottrell highlights that this approach not only disarms tumor defenses but also potentiates chemotherapy’s effectiveness. Given glioblastoma’s notorious resistance to treatment, such a dual-pronged approach—disruptive immunomodulation coupled with enhanced cytotoxicity—may finally offer a breakthrough in an otherwise bleak therapeutic landscape. The researchers stress that this synergy could shift current treatment paradigms by integrating biologically derived agents alongside standard chemotherapeutics.

Technologically, the use of neural crest-derived oral mucosal stem cells presents practical advantages. These cells secrete bioactive proteins and extracellular vesicles that can be isolated, produced, and stored without reliance on live stem cell cultures. This stability allows for scalable and consistent manufacturing, addressing a critical hurdle in translating stem cell therapies to widespread clinical application. Mass production of secretomes and vesicles could lead to off-the-shelf biologics tailored to overcome glioblastoma’s complex defense strategies.

Preclinical models remain essential to evaluate safety and efficacy before clinical trials. This study employed an innovative ex vivo system, transplanting human glioblastoma cells into murine brain tissue rather than whole-animal tumor models. This technique offers a realistic brain microenvironment to assess tumor dynamics and therapeutic impact while reducing animal usage and aligning with ethical research practices focused on replacement, reduction, and refinement. Utilizing brain slice culture allows for high-resolution analysis of tumor-cell interaction and treatment response in an anatomically relevant context.

Glioblastoma affects approximately 3,200 individuals annually in the UK alone, with dismal five-year survival rates—only about 5% achieve long-term remission. Despite aggressive multimodal treatment, tumor recurrence is almost inevitable due to residual resistant cancer stem cells and immune evasion mechanisms. Novel treatments capable of perturbing the tumor-host crosstalk hold promise for extending survival and improving quality of life. The stem cell secretome approach offers insight into harnessing endogenous cell communication pathways to counteract malignancy.

Crucially, the research elucidates a deeper understanding of glioblastoma’s immunological microenvironment. Unlike many cancers, glioblastoma co-opts inflammatory signaling to create a tumor-supportive niche, subverting immune surveillance. The study’s findings indicate that targeted modulation of inflammatory rebalancing—attenuating tumor-promoting signals while inducing anti-tumor immunity—can destabilize the tumor’s microenvironment, rendering it more susceptible to eradication. This immune-centric focus could pioneer new classes of brain cancer therapies beyond cytotoxic agents.

While this research marks a significant advance, challenges remain before translation to clinical application. Further validation in more complex in vivo models and dose-optimization studies are necessary to confirm safety and efficacy on a whole-organism level. Additionally, investigations into potential immunogenic side effects and long-term stability of secretome components will inform clinical trial design. Nevertheless, the scalable production potential and the non-reliance on live cells present a compelling case for rapid development.

In summary, the stem cell-derived secretomes from oral mucosal neural crest cells represent a promising avenue to undermine glioblastoma’s formidable defenses. By directly interfering with the tumor’s protective signaling while enhancing existing chemotherapy, this strategy introduces a novel class of biologics capable of shifting the balance in favor of the patient’s immune system. As glioblastoma survival rates have remained stagnant for decades, such innovative approaches leveraging the body’s own regenerative biology might finally herald a turning point in brain cancer treatment.

Looking forward, the research team envisions moving toward advanced models that better mimic the human patient condition, ultimately progressing to clinical trials. If successful, this approach could revolutionize not only glioblastoma therapy but also broaden to other malignancies where tumor immune evasion is a major obstacle. The prospect of manipulating stem cell secretomes to reprogram tumor microenvironments may unlock new frontiers in oncology, demonstrating the transformative power of regenerative medicine and immunotherapy synergy.

Subject of Research: Animals

Article Title: Neural Crest-Derived Stem Cell Secretomes and Extracellular Vesicles Disrupt Glioblastoma through Dual-Pathway Inflammatory Rebalancing

News Publication Date: 28-Apr-2026

Web References:

• https://doi.org/10.1007/s12015-026-11133-5
• https://braintumourresearch.org/pages/glioblastoma-awareness-week

References:
University of Reading study published in Stem Cell Reviews and Reports, 28 April 2026.

Keywords: Brain cancer, glioblastoma, neural crest-derived stem cells, secretomes, extracellular vesicles, chemotherapy enhancement, tumor microenvironment, immunomodulation, inflammatory rebalancing, regenerative medicine, oncology, stem cell therapy

Researchers at the University of Calgary have embarked on a pioneering clinical trial investigating the adjunctive use of high-dose niacin, also known as vitamin B3, in treating glioblastoma patients. This approach is grounded in compelling preclinical research demonstrating that niacin can rejuvenate immune cells compromised by the tumor microenvironment. Glioblastomas have a profound capacity to suppress the immune system, thereby facilitating tumor progression. By restoring immune function, niacin holds the potential to empower the body’s natural defenses in the fight against cancer.

The scientific rationale for this trial hinges on niacin’s ability to enhance the activity of critical immune cells, such as macrophages and microglia, within the brain. These cells play a pivotal role in surveilling and eliminating aberrant cells but become functionally impaired in glioblastoma. Experimental studies in animal models revealed that niacin supplementation prolonged survival by reversing immune suppression and promoting an antitumor immune response. These promising findings laid the groundwork for translational research, culminating in a Phase I and II clinical trial designed to establish safety, dosing parameters, and preliminary efficacy in human subjects.

This meticulously designed trial enrolled 24 patients with newly diagnosed glioblastoma, combining high-dose controlled-release niacin with standard-of-care chemotherapy and radiotherapy. The primary endpoint was progression-free survival at six months, with the study engineered to discontinue if improvements did not exceed a 20% threshold compared to historical data. Remarkably, 82% of participants remained progression-free at six months, marking a 28% improvement over previous studies. Such results are unprecedented in this notoriously difficult-to-treat malignancy, sparking cautious optimism among the scientific community.

The trial is spearheaded by oncologist Dr. Gloria Roldan Urgoiti and neuroscientist Dr. Wee Yong, both affiliated with the Hotchkiss Brain Institute and the Arnie Charbonneau Cancer Institute. These investigators emphasize the importance of rigorous safety monitoring given the known toxicities associated with megadoses of vitamins such as niacin. Excessive intake can lead to adverse effects including hepatotoxicity and gastrointestinal distress, necessitating a carefully controlled clinical environment.

From a mechanistic perspective, niacin’s role appears multifaceted. It serves as a precursor for nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic and DNA repair processes. By augmenting NAD+ levels, niacin enhances cellular resilience and the capacity of immune effector cells to attack cancer cells. Moreover, niacin modulates inflammatory signaling pathways, which may further contribute to restoring a tumoricidal microenvironment. This dual biochemical and immunological impact positions niacin as a uniquely promising adjunct therapy.

Ongoing research will continue to assess long-term outcomes and the potential for niacin to be integrated into standard treatment regimens. The study aims to complete a full cohort of 48 patients by early 2027, providing more robust data to support its preliminary positive findings. If successful, this therapy could represent a paradigm shift in managing glioblastoma, transforming a fatal diagnosis into a manageable chronic disease.

The psychological benefits for patients participating in such trials cannot be overstated. Edward Waldner expresses a renewed sense of hope and mental resilience as a direct result of being involved in this groundbreaking research. The feeling of actively contributing to medical advancement provides a critical boost to patient morale, which is often compromised during the rigorous treatment process for brain cancer.

Researchers caution that although niacin shows promise, it should not be self-administered outside of clinical trials due to the risk of toxicity. The precise dosing and controlled-release formulation used in the study are essential to achieving therapeutic effects without undue harm. Medical supervision remains paramount to ensure patient safety.

This study is supported by the Canadian Institutes of Health Research and the Alberta Cancer Foundation, underscoring significant institutional investment in translating bench research into clinical practice. The collaboration between clinicians and basic scientists exemplifies the interdisciplinary effort required to tackle complex diseases like glioblastoma.

The findings have recently been published in the peer-reviewed journal Neuro-Oncology, providing an important academic platform for dissemination and further scrutiny. As with all emergent therapies, ongoing peer review, replication, and larger Phase III trials will be critical steps to validate and expand upon these early results.

In the realm of immuno-oncology and neuro-oncology, the niacin trial stands as a beacon of innovation, blending nutrient science and cancer biology to combat one of the most intractable malignancies known to medicine. The story of Edward Waldner and this research initiative exemplifies the hope that can emerge from scientific perseverance and patient participation.

Subject of Research: People

Article Title: A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and interim phase II analysis

News Publication Date: 25-Nov-2025

Web References:
https://link.springer.com/article/10.1007/s11060-025-05351-z

References:
Roldan Urgoiti, G., Yong, W. et al. (2025). A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and interim phase II analysis. Neuro-Oncology.

Image Credits: Riley Brandt, University of Calgary

Keywords:
Glioblastomas, Brain cancer, Cancer, Vitamin B, Nicotinamides, Cells, Immunology